603351.SH
威尔药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 26.39
−1.31%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.3B | 1.3B | 1.3B | 1.2B | 1.1B |
| Cost of Revenue | 954.8M | 955.0M | 929.5M | 839.0M | 808.0M |
| Gross Profit | 386.8M | 380.0M | 367.3M | 316.8M | 303.0M |
| Operating Expenses | |||||
| R&D Expense | 82.4M | 81.5M | 71.6M | 55.6M | 53.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 98.5M | 97.0M | 101.4M | 108.7M | 115.4M |
| Selling & Marketing Expense | 17.1M | 16.9M | 14.5M | 12.8M | 10.9M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 221.3M | 215.6M | 207.9M | 198.7M | 197.3M |
| Cost and Expenses | 1.2B | 1.2B | 1.1B | 1.0B | 1.0B |
| Operating Income (EBIT) | 174.0M | 173.1M | 172.4M | 121.8M | 113.2M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 173.6M | 172.6M | 172.1M | 121.4M | 112.9M |
| Income Tax Expense | 23.5M | 23.7M | 26.9M | 12.3M | 18.4M |
| Bottom Line | |||||
| Net Income | 152.0M | 151.0M | 146.4M | 112.2M | 95.0M |
| Earnings from Cont. Ops | 150.1M | 149.0M | 145.2M | 109.1M | 94.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 152.0M | 151.0M | 146.4M | 112.2M | 95.0M |
| Per Share | |||||
| Basic EPS | CN¥1.12 | CN¥1.11 | CN¥1.08 | CN¥0.83 | CN¥0.72 |
| Diluted EPS | CN¥1.12 | CN¥1.11 | CN¥1.08 | CN¥0.83 | CN¥0.71 |
| Revenue Per Share | CN¥9.98 | CN¥9.82 | CN¥9.56 | CN¥8.55 | CN¥8.42 |
| Shares | |||||
| Basic Shares Outstanding | 134.4M | 136.0M | 135.6M | 135.2M | 132.0M |
| Diluted Shares Outstanding | 134.4M | 136.0M | 135.6M | 135.2M | 132.0M |
| Profitability Metrics | |||||
| EBITDA | — | 296.7M | 279.8M | 190.9M | 177.9M |
| D&A | — | 123.6M | 107.5M | 69.1M | 64.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026